FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014652020> ?p ?o ?g. }

• W2014652020 endingPage "1017.e1" @default.
• W2014652020 startingPage "1007" @default.
• W2014652020 abstract "ObjectiveBased on promising in vitro and in vivo activity of several histone deacetylase inhibitors in Hodgkin lymphoma (HL), we investigated SNDX-275, an oral class 1 isoform–selective histone deacetylase inhibitors in HL-derived cell lines.Materials and MethodsProliferation and cell death were examined by MTS assay, Annexin V/propidium iodide, and fluorescence-activated cell sorting analysis. Gene and protein expression were measured by reverse transcriptase polymerase chain reaction, Western blotting, and immunohistochemical analysis. A multiplex assay was used to determine cytokines and chemokines.ResultsSNDX-275 induced cell death in a dose- and time-dependent manner with an IC50 at the sub- and lower micromolar range at 72 hours. At the molecular level, SNDX-275 increased histone H3 acetylation, upregulated p21 expression, and activated the intrinsic apoptosis pathway by downregulating the X-linked inhibitor of apoptosis protein. SNDX-275 downregulated expression of antiapoptotic Bcl-2 and Bcl-xL proteins without altering Mcl-1 or Bax levels. Combination studies demonstrated that two Bcl-2 inhibitors (ABT-737 and obatoclax) significantly enhanced the effect of SNDX-275. SNDX-275 modulated the level of several cytokines and chemokines, including interleukin-12 p40-70, interferon-inducible protein-10, RANTES (regulated on activation, normal T expressed and secreted), interleukin-13, interleukin-4, and thymus and activation-regulated chemokine and variably induced the cancer/testis antigen expression of MAGE-A4 and survivin in HL cell lines.ConclusionsSNDX-275 has antiproliferative activity in HL cell lines, involving several mechanisms: induction of apoptosis, regulation of cytokines and chemokines, and alteration of cancer/testis antigens. Clinical investigation of SNDX-275 alone or in combination with Bcl-2 inhibitors is warranted in patients with HL. Phase 2 studies with SNDX-275 in HL are ongoing, and future clinical studies should investigate combinations with SNDX-275. Based on promising in vitro and in vivo activity of several histone deacetylase inhibitors in Hodgkin lymphoma (HL), we investigated SNDX-275, an oral class 1 isoform–selective histone deacetylase inhibitors in HL-derived cell lines. Proliferation and cell death were examined by MTS assay, Annexin V/propidium iodide, and fluorescence-activated cell sorting analysis. Gene and protein expression were measured by reverse transcriptase polymerase chain reaction, Western blotting, and immunohistochemical analysis. A multiplex assay was used to determine cytokines and chemokines. SNDX-275 induced cell death in a dose- and time-dependent manner with an IC50 at the sub- and lower micromolar range at 72 hours. At the molecular level, SNDX-275 increased histone H3 acetylation, upregulated p21 expression, and activated the intrinsic apoptosis pathway by downregulating the X-linked inhibitor of apoptosis protein. SNDX-275 downregulated expression of antiapoptotic Bcl-2 and Bcl-xL proteins without altering Mcl-1 or Bax levels. Combination studies demonstrated that two Bcl-2 inhibitors (ABT-737 and obatoclax) significantly enhanced the effect of SNDX-275. SNDX-275 modulated the level of several cytokines and chemokines, including interleukin-12 p40-70, interferon-inducible protein-10, RANTES (regulated on activation, normal T expressed and secreted), interleukin-13, interleukin-4, and thymus and activation-regulated chemokine and variably induced the cancer/testis antigen expression of MAGE-A4 and survivin in HL cell lines. SNDX-275 has antiproliferative activity in HL cell lines, involving several mechanisms: induction of apoptosis, regulation of cytokines and chemokines, and alteration of cancer/testis antigens. Clinical investigation of SNDX-275 alone or in combination with Bcl-2 inhibitors is warranted in patients with HL. Phase 2 studies with SNDX-275 in HL are ongoing, and future clinical studies should investigate combinations with SNDX-275." @default.
• W2014652020 created "2016-06-24" @default.
• W2014652020 creator A5000027373 @default.
• W2014652020 creator A5002306207 @default.
• W2014652020 creator A5002316929 @default.
• W2014652020 creator A5006134549 @default.
• W2014652020 creator A5012342629 @default.
• W2014652020 creator A5041105618 @default.
• W2014652020 creator A5048978229 @default.
• W2014652020 creator A5058837031 @default.
• W2014652020 creator A5068152076 @default.
• W2014652020 creator A5087013892 @default.
• W2014652020 date "2011-10-01" @default.
• W2014652020 modified "2023-10-16" @default.
• W2014652020 title "The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors" @default.
• W2014652020 cites W139356849 @default.
• W2014652020 cites W1929921628 @default.
• W2014652020 cites W1965008416 @default.
• W2014652020 cites W1967018540 @default.
• W2014652020 cites W1972149587 @default.
• W2014652020 cites W1972168709 @default.
• W2014652020 cites W1978664410 @default.
• W2014652020 cites W1979727285 @default.
• W2014652020 cites W1986250542 @default.
• W2014652020 cites W1991660464 @default.
• W2014652020 cites W1992740422 @default.
• W2014652020 cites W1993510744 @default.
• W2014652020 cites W2023661738 @default.
• W2014652020 cites W2024202249 @default.
• W2014652020 cites W2026450884 @default.
• W2014652020 cites W2026782606 @default.
• W2014652020 cites W2045167259 @default.
• W2014652020 cites W2046686330 @default.
• W2014652020 cites W2048807709 @default.
• W2014652020 cites W2050931169 @default.
• W2014652020 cites W2062424910 @default.
• W2014652020 cites W2066052727 @default.
• W2014652020 cites W2066077385 @default.
• W2014652020 cites W2069019880 @default.
• W2014652020 cites W2071115015 @default.
• W2014652020 cites W2076858918 @default.
• W2014652020 cites W2081422909 @default.
• W2014652020 cites W2082739830 @default.
• W2014652020 cites W2102650381 @default.
• W2014652020 cites W2109428091 @default.
• W2014652020 cites W2112900688 @default.
• W2014652020 cites W2113625315 @default.
• W2014652020 cites W2115354390 @default.
• W2014652020 cites W2123510004 @default.
• W2014652020 cites W2139292481 @default.
• W2014652020 cites W2141410747 @default.
• W2014652020 cites W2145879583 @default.
• W2014652020 cites W2156517973 @default.
• W2014652020 cites W2156748257 @default.
• W2014652020 cites W2157235421 @default.
• W2014652020 cites W2158859033 @default.
• W2014652020 doi "https://doi.org/10.1016/j.exphem.2011.07.002" @default.
• W2014652020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3177003" @default.
• W2014652020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21767511" @default.
• W2014652020 hasPublicationYear "2011" @default.
• W2014652020 type Work @default.
• W2014652020 sameAs 2014652020 @default.
• W2014652020 citedByCount "42" @default.
• W2014652020 countsByYear W20146520202012 @default.
• W2014652020 countsByYear W20146520202013 @default.
• W2014652020 countsByYear W20146520202014 @default.
• W2014652020 countsByYear W20146520202015 @default.
• W2014652020 countsByYear W20146520202016 @default.
• W2014652020 countsByYear W20146520202017 @default.
• W2014652020 countsByYear W20146520202018 @default.
• W2014652020 countsByYear W20146520202019 @default.
• W2014652020 countsByYear W20146520202020 @default.
• W2014652020 countsByYear W20146520202021 @default.
• W2014652020 countsByYear W20146520202022 @default.
• W2014652020 countsByYear W20146520202023 @default.
• W2014652020 crossrefType "journal-article" @default.
• W2014652020 hasAuthorship W2014652020A5000027373 @default.
• W2014652020 hasAuthorship W2014652020A5002306207 @default.
• W2014652020 hasAuthorship W2014652020A5002316929 @default.
• W2014652020 hasAuthorship W2014652020A5006134549 @default.
• W2014652020 hasAuthorship W2014652020A5012342629 @default.
• W2014652020 hasAuthorship W2014652020A5041105618 @default.
• W2014652020 hasAuthorship W2014652020A5048978229 @default.
• W2014652020 hasAuthorship W2014652020A5058837031 @default.
• W2014652020 hasAuthorship W2014652020A5068152076 @default.
• W2014652020 hasAuthorship W2014652020A5087013892 @default.
• W2014652020 hasBestOaLocation W20146520201 @default.
• W2014652020 hasConcept C104317684 @default.
• W2014652020 hasConcept C13373296 @default.
• W2014652020 hasConcept C153911025 @default.
• W2014652020 hasConcept C185592680 @default.
• W2014652020 hasConcept C190283241 @default.
• W2014652020 hasConcept C203014093 @default.
• W2014652020 hasConcept C2775934118 @default.
• W2014652020 hasConcept C2776202225 @default.
• W2014652020 hasConcept C2776914184 @default.
• W2014652020 hasConcept C2778305200 @default.
• W2014652020 hasConcept C31573885 @default.

• next